Trial intelligence / Profile preview

Fruquintinib combined with cadonilimab or PD-1/PD-L1 inhibitors in MSI-H/dMMR advanced colorectal cancer after prior immunotherapy failure

ChiCTR2400087227Phase 2Not yet recruiting

Sponsor

Fudan University Shanghai Cancer Center

Start

Jul 2024

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1